for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

AB Science SA

ABS.PA

Latest Trade

4.15EUR

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

3.10

 - 

5.38

As of on the Euronext Paris ∙ Minimum 15 minute delay

Pricing

Previous Close
4.15
Open
--
Volume
--
3M AVG Volume
1.06
Today's High
--
Today's Low
--
52 Week High
5.38
52 Week Low
3.10
Shares Out (MIL)
41.60
Market Cap (MIL)
180.50
Forward P/E
-6.29
Dividend (Yield %)
--

Next Event

Ab Science SA Annual Shareholders Meeting

Latest Developments

More

AB Science Raises EUR 10 Mln In Private Placement

AB Science Announces The Publication Of The Positive Phase 2/3 Clinical Trial With Masitinib

AB Science: Validation Of AB8939 Clinical Development Plan Through Regulatory Authority Scientific Advice Procedure

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About AB Science SA

AB Science SA, also known as AB Science, is a France-based pharmaceutical company specialized in the research, discovery, development and marketing of protein kinase inhibitors (PKIs). It is engaged in targeted therapies through tyrosine kinase inhibitors for treating diseases with high medical factor in the field of cancer, chronic inflammatory diseases, neurological degenerative disorders and central nervous systems diseases in both human and veterinary medicine. The main focus of the Company is the development of tyrosine kinase inhibitors, for instance Masitinib which is a tyrosine kinase inhibitor used as a veterinary medicine in the treatment of canine mast cell tumors. The Company is present in the United States and Europe. As of December 31, 2013, the Company operated though a subsidiary, AB Science USA LCC, based in the United States.

Industry

Biotechnology & Drugs

Contact Info

3 avenue George V

+33.1.47200014

http://www.ab-science.com/

Executive Leadership

Alain Moussy

Chairman of the Board, Chief Executive Officer

Denis Gicquel

Deputy Chief Executive Officer

Laurent Guy

Chief Financial Officer

Jean-Pierre Kinet

Director

Patrick Moussy

Director

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (EUR)

2016

-0.780

2017

-0.750

2018

-0.690

2019(E)

-0.660
Price To Earnings (TTM)
--
Price To Sales (TTM)
106.11
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
-148.17
Return on Equity (TTM)
-71.31

Latest News

BRIEF-AB Science: Positive Recommendation Of IDMC Following Interim Analysis Of Study AB12005

* ANNOUNCED ON WEDNESDAY POSITIVE RECOMMENDATION OF THE INDEPENDENT DATA MONITORING COMMITTEE (IDMC), FOLLOWING INTERIM ANALYSIS OF STUDY AB12005 IN THE FIRST-LINE TREATMENT OF PANCREATIC CANCER

BRIEF-AB Science Presents New Preclinical Data For Masitinib In ALS

* ANNOUNCED ON TUESDAY NEW PRECLINICAL DATA FOR MASITINIB IN ALS AT 2019 MUSCULAR DYSTROPHY ASSOCIATION CONFERENCE

BRIEF-AB Science FY Operating Loss Down At 28.4 Million Euros

* FY NET LOSS EUR 27.1 MILLION VERSUS LOSS OF EUR 27.7 MILLION YEAR AGO

BRIEF-AB Science Announces Negative Opinion From CHMP

* REG-AB SCIENCE ANNOUNCES THAT THE CHMP HAS ADOPTED A NEGATIVE OPINION FOR THE MARKETING AUTHORIZATION OF MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS

BRIEF-Ab Science Says IDMC Recommends Continuation Of masitinib Phase 3 Study With No Requirement To Increase Sample Size

* REG-AB SCIENCE ANNOUNCES THAT BASED ON INTERIM ANALYSIS, IDMC RECOMMENDED THE CONTINUATION OF THE MASITINIB PHASE 3 STUDY IN PROGRESSIVE MULTIPLE SCLEROSIS WITH NO REQUIREMENT TO INCREASE THE SAMPLE SIZE

BRIEF-AB Science announces publication of preclinical data showing that masitinb is capable of counteracting resistance to oncology treatments

* REG-AB SCIENCE ANNOUNCES THE PUBLICATION OF PRECLINICAL DATA SHOWING THAT MASITINB IS CAPABLE OF COUNTERACTING RESISTANCE TO ONCOLOGY TREATMENTS

BRIEF-AB science announces ‍preclinical data showing protective effect of masitinib

* PRECLINICAL DATA SHOWING PROTECTIVE EFFECT OF MASITINIB ON PERIPHERAL NERVOUS SYSTEM IN ALS PUBLISHED IN JOURNAL OF CLINICAL INVESTIGATION INSIGHT Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-AB Science: CHMP adopts negative opinion for Masitinib marketing authorization

* REG-AB SCIENCE ANNOUNCES THAT CHMP ADOPTED A NEGATIVE OPINION FOR MASITINIB MARKETING AUTHORIZATION IN INDOLENT SYSTEMIC MASTOCYTOSIS AFTER REASSESSMENT

BRIEF-AB Science net loss narrows to 13.5 million euros

* NET LOSS OF 13.5MEUR IN FIRST HALF OF 2017, A DECREASE OF 8.4% AS COMPARED WITH FIRST HALF OF 2016 (14.7MEUR )

BRIEF-AB Science announces issuance of a new european patent

* REG-AB SCIENCE ANNOUNCES ISSUANCE OF A NEW EUROPEAN PATENT FOR PROTECTING THE USE OF MASITINIB IN PANCREATIC CANCER PATIENTS

BRIEF-AB Science presents supportive data from its phase 3 study in severe systemic mastocytosis

* PRESENTS SUPPORTIVE DATA FROM ITS PHASE 3 STUDY IN SEVERE SYSTEMIC MASTOCYTOSIS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-EU Medicines Agency recommends against approval of AB Science mastocytosis drug Masitinib

* EU Medicines Agency recommends approval of Valeant Pharmaceuticals Inc psoriasis drug Brodalumab

BRIEF-AB Science presents Phase 3 data for Masitinib in amyotrophic lateral sclerosis (ALS)

* PRESENTS PHASE 3 DATA FOR MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS (ALS)

BRIEF-Ab Science: CHMP adoptes negative opinion for masitinib in indolent systemic mastocytosis

* REG-AB SCIENCE ANNOUNCES THAT CHMP HAS ADOPTED A NEGATIVE OPINION FOR MASITINIB IN INDOLENT SYSTEMIC MASTOCYTOSIS, PRIMARILY DUE TO GCP INSPECTION FINDINGS

BRIEF-Trading resumption on shares of AB Science

* Announced today that trading on ordinary shares issued by AB Science will resume on Euronext Paris as of May 16, 2017 at 0900 CET Further company coverage: (Gdynia Newsroom)

BRIEF-AB Science - ANSM requested temporary suspension of masitinib studies

* Notification from ANSM requesting temporary suspension of ongoing masitinib studies until compliance is confirmed by an external audit

BRIEF-AB Science FY net loss widens to 27.7 million euros

* Reported on Monday FY net revenues of 1.5 million euros ($1.64 million) versus 2.3 million euros a year ago

BRIEF-AB Science issues 1.2 mln new ordinary shares - Euronext

* AB Science SA issues 1,241,831 new ordinary shares, which will be listed on Euronext Paris market as of April 4, 2017 Further company coverage: (Gdynia Newsroom)

BRIEF-Ab Science announces that masitinib passed its non-futility test at 2 years

* Announces that masitinib study in primary and secondary progressive forms of multiple sclerosis has passed its non-futility test at 2 years

BRIEF-AB Science announces positive results of final analysis from study AB10015

* Announces positive top-line results of final analysis from study AB10015 of masitinib in amyotrophic lateral sclerosis (ALS)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up